Two competing approaches to protecting newborns from RSV—one of the most serious respiratory threats in infancy—now show equivalent effectiveness in preventing hospitalization. This finding could reshape how pediatricians and expectant mothers approach RSV prevention during pregnancy and early infancy. French researchers analyzed national health data from over 35,000 infants to directly compare maternal vaccination with the RSVpreF vaccine during late pregnancy versus administering nirsevimab antibodies to newborns after birth. Both strategies demonstrated similar protective effects against RSV-related hospitalizations requiring medical intervention. The maternal vaccination approach works by transferring protective antibodies across the placenta during the final weeks of pregnancy, while nirsevimab provides passive immunity through direct antibody administration to infants before hospital discharge. This head-to-head comparison fills a critical knowledge gap that has persisted since both preventive strategies received regulatory approval. Previous studies examined each intervention separately against historical controls, making direct effectiveness comparisons impossible. The equivalent protection levels suggest that healthcare systems and families now have genuine choice in RSV prevention strategies, potentially influencing prenatal care protocols and newborn discharge procedures. However, this represents data from a single RSV season in one healthcare system, and longer-term durability differences between the approaches remain unexplored. The findings support evidence-based decision-making but highlight the need for multi-season data to fully understand optimal timing and population-specific effectiveness of these complementary prevention strategies.